TABLE 1.

Key take‐home messages and clinical perspective

1	Microvascular disease predicts macrovascular disease; achieving and maintaining glycaemic control plays a critical role in reducing microvascular and macrovascular complications for people with T2D
2	Separately, and independent of glycaemic control, agents from the SGLT2 inhibitor and GLP‐1RA class have been shown to reduce CV risk in individuals with established/high risk of CVD
3	Holistically, both achievement of glucose control and choice of appropriate therapy are equally important for reducing risk of complications
4	One size does not fit all in T2D; HbA1c goals and treatments need to be individualized, with glycaemic targets achieved safely
5	Avoidance of therapeutic inertia is key to achieving HbA1c targets in all people with T2D, with early, sustained glycaemic control associated with reduced complication risk
6	Physiological control (e.g., less glycaemic variability, more time in range) is associated with a lower risk of CV complications; monitoring technology has the potential to facilitate more physiological control and guide therapeutic needs

Abbreviations: CVD, cardiovascular disease; CVOT, cardiovascular outcomes trial; GLP‐1RA, glucagon‐like peptide‐1 receptor agonist; HbA1c, glycated haemoglobin; SGLT2, sodium‐glucose cotransporter‐2.